BOSTON, July 28, 2026
Atea Pharmaceuticals announced positive topline results from its pivotal Phase 3 C-BEYOND trial, with its investigational fixed-dose combination of bemnifosbuvir/ruzasvir (BEM/RZR) successfully meeting both the primary and secondary endpoints in patients with chronic hepatitis C virus (HCV) infection. The once-daily oral regimen achieved statistical non-inferiority to the current standard-of-care sofosbuvir/velpatasvir (SOF/VEL; Epclusa®) in the modified intent-to-treat population, marking the first successful head-to-head Phase 3 comparison between HCV treatment regimens in a global development program. Among 905 patients enrolled across the United States and Canada, BEM/RZR achieved a 93.9% sustained virologic response (SVR) compared with 94.8% for SOF/VEL, meeting the predefined statistical criteria while demonstrating comparable cure rates across patients with and without compensated cirrhosis.
Eight-Week Regimen Highlights Potential Best-in-Class Profile
The study reinforces the potential of BEM/RZR as a shorter 8-week treatment option for patients without cirrhosis, representing approximately 80% to 90% of individuals living with HCV in the United States. In this patient group, BEM/RZR achieved a 93.5% SVR rate after eight weeks of therapy, while patients receiving SOF/VEL required 12 weeks of treatment to achieve a 94.6% SVR rate. Among patients with compensated cirrhosis, where both treatment arms received 12 weeks of therapy, BEM/RZR and SOF/VEL each achieved a 95.4% SVR rate. The investigational regimen also demonstrated low rates of virologic failure, successfully met secondary endpoints including the per-protocol analysis, and was generally safe and well tolerated, with no drug-related serious adverse events or treatment discontinuations, supporting its potential as a differentiated treatment option for chronic HCV infection.
Shorter Treatment Could Improve Global HCV Elimination Efforts
According to Atea Pharmaceuticals, the combination of high cure rates, shorter treatment duration, minimal drug-drug interaction potential, and the flexibility to be taken with or without food could simplify treatment and improve patient adherence. Company Founder and Chief Executive Officer Dr. Jean-Pierre Sommadossi noted that the findings align with the World Health Organization’s goal of eliminating hepatitis C as a public health threat. Clinical investigator Dr. Eric Lawitz emphasized that many patients with HCV manage multiple chronic conditions requiring several medications, making a shorter, convenient regimen with fewer interaction concerns particularly valuable. The company believes the investigational therapy could help accelerate test-and-treat strategies, enabling healthcare providers to diagnose and initiate treatment more efficiently while reducing barriers to care for patients with complex medical needs.
Advertisement
Global Phase 3 Program Continues Toward Regulatory Submission
The C-BEYOND study represents one component of Atea Pharmaceuticals’ global Phase 3 HCV development program, which also includes the fully enrolled C-FORWARD trial involving more than 880 treatment-naïve patients across 17 countries outside North America. While C-BEYOND primarily evaluated HCV genotypes commonly found in the United States and Canada, C-FORWARD is expected to provide additional efficacy data across a broader range of global HCV genotypes, with topline results anticipated in early 2027. Atea Pharmaceuticals plans to present detailed Phase 3 findings at upcoming medical conferences and submit the results for publication in peer-reviewed journals. With an estimated 50 million people worldwide living with hepatitis C, including up to 4 million people in the United States, the successful Phase 3 outcome positions BEM/RZR as a promising next-generation antiviral therapy that could offer a best-in-class combination of efficacy, convenience, and treatment simplicity for patients affected by chronic HCV.
Source:Atea Pharmaceuticals, press release
